cosmetics-biomarkers-2019-keynote

6 / 7

Page 17
Notes:
allied
academies
Case Reports in Surgery and Invasive Procedures | Volume 3
Biomarkers
Plastic and Cosmetic Surgery
International Conference on
International Conference on
Joint Event
&
March 11-12, 2019 | London, UK
Identification of novel prognostic and predictive biomarkers
is purported to improve the classification and management
of metastatic colorectal cancer (mCRC) and is the primary
thrust of my research.
In this context we have identified a single nucleotide
polymorphism (SNP) within DNA-repair enzyme O6-
methylguanine DNAmethyl-transferase (MGMT) by analyzing
78 mCRC patients. In a univariate analysis, patients with
the TT genotype (12% of patients) had a median OS of 61.8
months, while those with homozygous GG or heterozygous
GT had a median OS of 29.3 months (P=0.06). Further, in
multivariate modeling, patients with the TT genotype had
longer survival when compared to those with homozygous
GG or heterozygous GT (HR 0.30; 95% CI:0.10-0.89, P= 0.03),
after adjusting for known clinical prognostic parameters such as
gender, race, ageat diagnosis, number ofmetastatic sites, number
of chemotherapy lines receivedandCEAat diagnosis. Thepatients
with the TT genotype had 70% reduced risk of death. We have
also analyzed the expression of DNA excision repair protein
ERCC-1 in 56 mCRC patients’ pre and post oxaliplatin regimen
by immunoblot and real time quantitative PCR. Median PFS was
190 and 237 days in the two groups respectively (log-rank test
HR 2.35, CI 1.005-5.479; p=0.0182) Thus, increase in ERCC gene
expression post platinum-based chemotherapy is a potential
marker of drug resistance. Further in effort to understand the
immune responses in mCRC we generated tissue microarray
from 137 mCRC patients and performed immune histochemical
staining for four different markers of B7 family of immune
modulators. The analysis showed that increase expression of
B7H3 is a potential biomarker of worse overall survival among
patients of different racial origin. Race was designated as non-
Hispanic white (NHW, n=25), non-Hispanic black (NHB, n=63),
and Hispanic (n=49). Median survival was 747days for NHWand
565days for H patients (p=0.036, HR=1.6, 95% CI=1.03-2.58).
Speaker Biography
Radhashree Maitra is a Senior Scientist at Montefiore medical centre and also an associate
professorofbiologyatYeshivaUniversity.Shecompletedherbachelor’sdegree inchemistry
(honours) with specialization in Biochemistry. She did her masters in Biochemistry with
specialization in molecular Biology and also a Ph.D in Biophysics, molecular biology
and genetics from Calcutta University in 1997. She qualified for UGC (University Grants
commission, India) National Eligibility Test (NET) award in 1989 and then “Senior Research
Fellowship” award from CSIR-INDIA in 1993. She did her first post-doctoral research at
Washington University in St. Louis, Missouri and her second postdoctoral research at Albert
Einstein College of Medicine of Yeshiva University, Bronx New York. She has around 28
original peers reviewed publications.
e:
Radhashree Maitra
Yeshiva University, USA
Identification of biomarkers for precision management of metastatic
colorectal cancer